A Brief Historic Overview of Clinical Disorders Associated with Tryptophan: The Relevance to Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM).

Adele Blankfield
Kew, Australia. Corresponding author email: gjshnier@bigpond.net.au

Abstract: Last century there was a short burst of interest in the tryptophan related disorders of pellagra and related abnormalities that are usually presented in infancy.\textsuperscript{1,2} Nutritional physiologists recognized that a severe human dietary deficiency of either tryptophan or the B group vitamins could result in central nervous system (CNS) sequelae such as ataxia, cognitive dysfunction and dysphoria, accompanied by skin hyperpigmentation.\textsuperscript{3,4} The current paper will focus on the emerging role of tryptophan in chronic fatigue syndrome (CFS) and fibromyalgia (FM).

Keywords: tryptophan, pellagra, gamma interferon, chronic fatigue syndrome, fibromyalgia, vitamin B12
Tryptophan Metabolism

Until the year 2000, research into the specific attributes of the serotonin pathway and its role in neuro-psychiatric disorders disorders was double that of other aspects of tryptophan metabolism. Experimental tryptophan depletion tests were devised to ascertain the influence of serotonin metabolism on cognition, mood and behavior. Brief tryptophan depletion tests in normal human subjects, for example, provided consistent evidence for its role in impaired memory consolidation and reduced visual perception. Older studies of prolonged dietary depletion of both tryptophan and niacin were known to lead to severe pellagra, with neurological and extensive inflammatory mucosal membrane changes. These occurred within one to two months of a depleted diet. In recent decades, however, the involvement of this essential amino acid in the kynurenine pathway has been elucidated. This has in part explained some of the pathological processes of pellagra.

Protein catabolism had long been recognized as the big picture metabolic response to all noxious bodily stimuli such as trauma, infection and neoplastic processes. Upon further analysis of the separate amino-acid constituents of proteins, the degradation of tryptophan emerged as a major contributor to the catabolic process amongst its other critical functions such as neuromodulation. The intimate relationship in the kynurenine pathway between tryptophan, gamma-interferon and 2-3-dioxygenase (IDO) as an immuno-modulatory mechanism has since been substantiated. The kynurenine pathway is also linked to the synthesis of nicotinamide adenine dinucleotide (NAD) from quinolinic acid, and it is up-regulated by neurodegenerative and other inflammatory triggers. This discovery of the existence of two tryptophan metabolic pathways in the CNS and peripheral nervous system has challenged researchers to discriminate between the consequences activation of these dual paths.

There have been subsequent advances in technologies, such as developments in magnetic resonance imaging (MRI) and positron emission tomography (PET), as well as an increased range of available biochemical and genetic tests. These newer techniques have generated data from specialist molecular biologists at cellular and micrometabolic levels. This sophisticated phase of research has increased our understanding of the physiological mechanisms that underpin basic principles and observations in medicine. The information is extremely complex, and there tends to be a time lag before it is incorporated into clinical application.

Some Clinical Disorders

The gastrointestinal tract is the nutrient gateway to the body and little is known about tryptophan activity in this area. The combination of malnutrition, malabsorption and metabolic inefficiencies is difficult to unravel. Resultant physical defects from tryptophan depletion can range from mild to severe and can be hard to detect and interpret. Tryptophan absorption and metabolic utilization are vulnerable to both primary inborn genetic errors and secondary gut disturbances. In addition, there are several inherited autoimmune diseases of the bowel that affect absorption, such as celiac and Crohn's disease. These conditions usually do not become apparent until adulthood. Case reports of intestinal autoantibodies to tryptophan hydroxylase have occurred in adults, associated with bowel dysfunction and other systemic autoimmune disorders. At the present time, these various conditions are not completely understood.

Rose (1972) outlined the clinical issues of that era. He also detailed three inborn errors including Hartnup Disease, hypertryptophanemia and 3-hydroxy-kynureninuria. Sabator and Ricos reported the presence of kynurenine irregularities in 5% of 830 institutionalized children with mental retardation. Other primary abnormalities of childhood including tryptophanol glycine absorption disorders have subsequently been documented.

Hartnup Disease is an autosomal recessive condition that is no longer included in neonatal screening programs. This disease is thought to have the same community prevalence as phenylketonuria. It is noted for its clinical variability and onset can occur in adulthood. The physical phenomena resembling pellagra in Hartnup Disease responds to treatment with either niacinamide or neomycin. Carcinoid tumours, drug side effects, nutritional inadequacies can also present with secondary pellagrous states.

The Relevance of Tryptophan to CFS/FM

The potential connection between the kynurenine pathway and CFS was initially made in 1991 and with FM in 1993. This hypothesis was recently revived as more evidence of tryptophan pathway
dysfunction in CFS/FM has since accrued. CFS/FM could involve serum tryptophan level deficiency, and impaired immune-modulatory function has been demonstrated at the gamma-interferon, IDO stage of metabolism. In addition, there appears to be some resemblance between CFS/FM irregularities and those found in other medical conditions.

**Clinical Outline**

CFS/FM constitutes a definite single syndrome. There is a consistent, recurring pattern of core symptoms in affected populations. Some physicians prefer the hybrid classification of overlap syndrome, whereas a few patient support groups opt for the term myalgic encephalomyelitis (ME). The differences lie in theoretical explanatory constructs. Uncertain fluctuations in the course and outcomes of individual patients confound some aspects of scientific analysis.

The signs and symptoms of the condition are well documented in the specialist CFS/FM literature. Patients present with extreme exhaustion, which is aggravated by exertion and altered sleep patterns. Concentration and memory is impoverished and patients experience visual disturbances and unfathomable pain. They may suffer inexplicable gastrointestinal and urogenital tract discomforts. Amongst less obvious symptoms are ataxia, myopathy, lowered thyroid and cortisol levels, food intolerances and puzzling skin conditions.

**Tryptophan Status in CFS/FM**

In 1975, Moldofsky and colleagues looked to serotonin in an attempt to explain the “non-restorative sleep syndrome” of fibrositis (later termed fibromyalgia). In a 1978 study, patients’ tryptophan levels were noted to be lowered. This observation was repeated by Yunus and colleagues in 1992. The extensive studies of Russell and colleagues were undervalued at that time. Russell and colleagues discovered an abnormality in the conversion stage of 3-hydroxy kynurenine in the CNS in FM patients. Since then, research into the attributes of tryptophan in the context of CFS/FM has continued. A couple of subsequent studies examined amino acid urinary profiles and other biochemical parameters in CFS patients and controls, without specific mention of tryptophan.

There are several possible explanations for the observed decrease in tryptophan levels in CFS/FM patients. This decrease may be due to any primary genetic disorder, or may be due to malabsorptions created by an idiopathic irritable bowel syndrome, food intolerances, bacterial overgrowth and other bowel disorders. Silent or chronic infections can increase metabolic demands for tryptophan and vitamin B12. Nicotinamide absorption can be reduced through severe diarrhea. These listed observations imply that tryptophan, nicotinamide and B12 deficiencies can become a complication of CFS/FM. Evidence for the requirement of L-carnitine, zinc and intravenous vitamin solutions is circumstantial. This question of nutrient substrate deficiency warrants investigation along formal medical protocols rather than the less structured methods of complementary and alternative medicine models. It is also important to establish if there is a point at which the decline in available metabolic fuel reaches a critical level and structural morphological damage becomes irreversible, leading to chronically impaired health.

**Gamma-Interferon and Other Immune Dysfunctions**

CFS/FM has, in part, been recognized as an immune deficiency syndrome. Bell was at a loss to explain the immunological profile of the CFS/FM patient; however, he appreciated that it was still early days in the field of cytokine research. He divided the observed irregularities into categories, based on either overactivity or underactivity of the immune system. Underactivity was reflected in a decreased number and function of natural killer cells, a decreased mitogen response and decreased antibody levels, particularly in the IgG subclasses, in response to infections. In contrast, up-regulation or overactivity of the immune system involved elevated levels of gamma-interferon and other cytokines. CD8 lymphocytes might increase in number with a consequent effect on the CD4:CD8 ratio. Multiple allergies (atopy) and autoantibody production could be activated. He later considered whether the prolonged malaise observed in CFS could be due to the persistence of infection caused by impaired patient immunity. He suggested that another factor might involve failure of an initial immune defense response by the host, leading the host to shut down and therefore be unable to proceed along the pathway of resolution.
Lloyd and colleagues had already documented aspects of “disordered immune regulation” in 1989 in their CFS patients. They discovered that this abnormality related to the host response and could not be attributed to any specific viral infectious agent. They were aware that the therapeutic use of interferons in other medical conditions could produce severe CFS-like symptoms as a side effect. They anticipated that gamma-interferon would be implicated in CFS illness complications.

Kerr and colleagues performed extensive studies of patients infected with parvovirus 19. They detected the continued presence of the alpha-tumor necrosis factor and gamma-interferon in both the acute and convalescent phases of this infection. They associated these anomalies with the prolongation of a fatigued state. Kerr and his co-workers were amongst those researchers who proposed that “immune control of the virus may not be efficient”. This feature might, in addition, explain the presence of under-recognized neuropathic pain of subclinical Zoster sine Herpete and of any other infectious and avitaminotic states in CFS/FM patients.

**Conclusion**

Contemporary tryptophan research examines the up-regulation of the kynurenine pathway by neurological and psychiatric disorders and autoimmune, neoplastic and infectious diseases. The ultimate aims of these studies are to further the understanding of the neurological consequences of these illnesses and to improve their treatment prospects.

There are comparative clusters of signs and symptoms in both patients with CFS/FM and in those whose conditions relate predominantly to the kynurenine pathway. Thus, CFS/FM patients could benefit from investigations searching for primary errors of tryptophan metabolism and other kynurenine pathway pathologies.

In 1986, Mersky stated that “a lack of adequate technology and a proper unwillingness to undertake hazardous investigations for obscure symptoms may encourage a false attribution of psychological symptoms to physical illness”. He listed examples of some conditions that had been reclassified as organic in nature. He recommended that the diagnostic status of the patient be reviewed if warranted.

**Author Contributions**

Wrote the first draft of the manuscript: AB. Contributed to the writing of the manuscript: AB. Jointly developed the structure and arguments for the paper: AB. Made critical revisions and approved final version: AB. All authors reviewed and approved of the final manuscript.

**Funding**

Author(s) disclose no funding sources.

**Competing Interests**

Author(s) disclose no potential conflicts of interest.

**Disclosures and Ethics**

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest.

**References**

1. Rose DP. Aspects of tryptophan metabolism in health and disease: a review. *J Clin Pathol*. 1972;25(1):17–25.
2. Lehman J. Mental and neuromuscular symptoms in tryptophan deficiency: Pellagra, carcinoidosis, phenylketonuria, Hartnup disease and disturbances of tryptophan metabolism induced by p-chlorophenylalanine, levodopa and α-methyl dopa. A review with special reference to mental symptoms in a selected material of carcinoid patients. *Acta Psychiatr Scand*. 1972;48 (Suppl 237):5–28.
3. Heseker H, Kübler W, Pudel V, Westenhöffer J. Psychological disorders as early symptoms of mild-moderate vitamin deficiency. *Ann N Y Acad Sci*. 1992;669:352–7.
4. Lisham WA. *Organic Psychiatry*. 2nd edition. New York: Blackwell Scientific Publications; 1987.
5. Sidransky H. *Tryptophan. Biochemical and Health Implications*. Boca Raton: CRC Press; 2001.
6. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. *Science*. 1971;173(3992):149–52.
7. Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-tryptophan: basic metabolic functions, behavioural research and therapeutic indications. *Int J Tryptophan Res*. 2009;2:45–60.
Clinical disorders associated with tryptophan, CFS and FM

8. Rubinsztein JS, Rogers RD, Riedel WJ, Mehta MA, Robbins TW, Sahakian BJ. Acute dietary tryptophan depletion impairs maintenance of “afferent set” and delayed visual recognition in healthy volunteers. Psychopharmacology (Berl). 2001;154(3):319–26.

9. Wilson JD. Disorders of vitamins: deficiency, excess and errors of metabolinism. In: Petersdorf RG, editor. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 1983.

10. Chen V, Guillemin GJ. Kynurenine pathway metabolites in human disease and healthy states. Int J Tryptophan Res. 2009;2:1–19.

11. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med. 2006;8(20):1–27.

12. Assennat K, Wirlein K, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364(1–2):82–90.

13. Brandacher G, Margreiter R, Fuchs D. Implications of IFN-γ-mediated tryptophan catabolism on solid organ transplantation. Curr Drug Metab. 2007;8(3):273–82.

14. Capuron L, Schroecksnadel S, Fèrt C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropyschiatric symptoms. Biol Psychiatry. 2011;70(2):175–82.

15. Taylor MW, Feng GS. Relationship between interferon-γ, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 1999;5:2516–22.

16. Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome using position emission tomography and [11C]WAY-100635. Biol Psychiatry. 2003;57(3):239–46.

17. Perkin GD, Murray-Lyon I. Neurology and the gastrointestinal system. J Neurol Neurosurg Psychiatry. 1998;65(3):291–300.

18. Hogenauer C, Hammer HF. Maldigestion and malabsorption. In: Sleisenger and Fordtran’s gastrointestinal and liver disease: Pathophysiology, Diagnosis, Management. 5th edition. Feldman M, Friedman LS, Brandt LJ, editors. Philadelphia: Saunders Elsevier; 2006.

19. Ledochowski M, Widner B, Murr C, Sperner-Unterweger B, Fuchs D. Fructose malabsorption is associated with decreased plasma tryptophan. Scand J Gastroenterol. 2001;36(4):367–71.

20. Haverback BJ, Dyce B, Thomas VH, Indole metabolism in the malabsorption syndrome. N Engl J Med. 1960;26:754–7.

21. Scrivner CR. Abnormalities of tryptophan metabolism in a patient with malabsorption syndrome. J Lab Clin Med. 1961;58:908–19.

22. Montgomery RD, Beale DJ, Schneider R. Post-infective malabsorption syndrome: a sprue syndrome. Brit Med J. 1973;2(5861):265–8.

23. Bender Da. Introduction to nutrition and metabolism. 4th edition. Boca Raton: CRC Press; 2008.

24. Ekwall O, Hedstrand H, Grimmelius L, et al. Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet. 1998;352(9124):278–83.

25. Ekwall O, Hedstrand H, Haavik J, et al. Phenytoin-dependent hydroxylases as autoantigens in autoimmune polyclonine syndrome type 1. J Clin Endocrinol Metab. 2000;85(9):2944–50.

26. Gianetti G, Stouch T, Yu W, et al. Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by co-crystal structures and kinetic analyses. Curr Chem Genomics. 2010;4:19–26.

27. Tack J, Janssen P, Wouters M, Boecxstaens G. Targeting serotonin synthesis to treat irritable bowel syndrome. Gastroenterology. 2011;141(2):420–2.

28. Sabater J, Ricós C. Abnormalities of tryptophan metabolism (kynurenine pathway) found in a group of 830 mentally retarded children. Clin Chim Acta. 1974;56(2):175–86.

29. Heelý AF, Heelé MY, Hardy J, Soothill JF. A disorder of tryptophan metabolismo in chronic granulomatous disease. Arch Dis Child. 1970;45(242):485–90.

30. Salih MA, Bender DA, McCleaner GM. Lethal familial pellagra-like skin lesion associated with neurologic and developmental impairment and the development of cataracts. Pediatrics. 1985;76(3):787–93.

31. Assmann B. Biogenic amines and pterins in cerebrospinal fluid: some pitfalls with interpretation. Future Neurosci. 2006;1(5):651–7.

32. Hyland K. Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J Nutr. 2007;137 (Suppl 1):1568S–72.

33. Schott DA, Nicolas J, de Vries J, Keularts IM, Rubiso-Gozalbo ME, Gerver WJ. Disorder in the serotoninergic system due to tryptophan hydroxylisation impairment: a cause of hypothalamic syndrome? Horm Res Paediatr. 2010;73(1):68–73.

34. Wilken B, Yu JS, Brown DA. Natural History of Hartnup Disease. Arch Dis Child. 1977;52(1):38–40.

35. Seow HF, Bröer S, Bröer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nature Genetics. 2004;36(9):1003–7.

36. Oakley A, Wallace J. Hartnup disease presenting in an adult. Clin Exp Dermatol. 1994;19(5):407–8.

37. Pooleti R, Sirtori C, Spono PA. Clinical relevance of drugs affecting tryptophan transport. Annu Rev Pharmacol. 1975;15:73–81.

38. Fuchs D, Weiss G, Wachter H. Pathogenesis of chronic fatigue syndrome. J Clin Psychiatry. 1992;53(8):296–6.

39. Russell JJ, Vipraio GA, Acrworth J. Abnormalities in the central nervous (CNS) metabolism of tryptophan (TRY) to 3-hydroxy kynurenine (OHKY) in fibromyalgia syndrome (FS). Arthritis Rheum. 1993;36(9):5222.

40. Blankfeld A. Kynurenine pathway hypothesis: the nature of the Chronic Fatigue Syndrome (CFS) Revised. Int J Tryptophan Res. 2011;4:47–8.

41. Popper, Karl R. Conjectures and Refutations. The growth of scientific knowledge. London: Routledge and Kegan Paul; 1972.

42. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev. 2000;5(2):93–108.

43. Werbach MR. Serotonin in chronic fatigue syndrome and fibromyalgia. Townsend letter for doctors and patients. Nov 2001.

44. Kerr JR, Barah F, Mattei DL, et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalesce parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol. 2001;82(Pt 12):3011–9.

45. Constant EL, Adam S, Gilliain B, Lambert M, Masquellier E, Seron X. Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls. Clin Neurol Neurosci. 2011;3(4):295–302.

46. Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Brit J Psychiat. 1990;156:534–40.

47. Bell David S. The Doctor’s Guide to Chronic Fatigue Syndrome. Boston: Addison-Wesley Publishing Company; 1995.

48. Russell JJ. The fibromyalgia syndrome: a clinical case definition for practitioners. J of Musculoskeletal Pain. 2003;11(4): Binghamton: Haworth Medical Press, 2003.

49. Carruthers BM, van de Sande M. Myalgic encephalomyelitis/fibromyalgia Syndrome: A clinical case definition and guidelines for medical practitioners. A consensus document. JCPFS. 2003;11(1):7–115.

50. Park DC, Glass IM, Minear M, Crotter J. Cognitive Function in fibromyalgia patients. Arthritis Rheum. 2001;44(9):2125–33.

51. Rodríguez-Andreu J, Ibáñez-Bosch R, Portero-Vázquez A, Masramon X, Rejas J, Gálvez R. Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination. BMC Musculoskelet Disord. 2009;10:162.

52. Nickel JC, Tripp DA, Pontari M, et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol. 2010;184(4):1358–63.

53. Clarke G, McKernan DP, Gasmer G, et al. A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol. 2012:3:90.

54. Moldofsky H, Scarisbrick P, Portero-Vázquez A, Masramon X, Rejas J, Gálvez R. Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination. BMC Musculoskeletal Disord. 2009;10:162.

55. Sunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol. 1992;19(1):790–4.

56. Schwartz MJ, Offenbaecher M, Neumeister A, Ackenheil M.  Experimental and clinical evidence for a role of tryptophan in the pathogenesis of fibromyalgia syndrome. Int J Tryptophan Res. 2010;4:19–26.
57. Bazzichi L, Palego L, Giannaccini G, et al. Altered amino acid homeostasis in subjects affected by fibromyalgia. Clin Biochem. 2009;42(10–11):1064–70.
58. Jones MG, Cooper, Amjad S, Goodwin CS, Barron JL, Chalmers RA. Urinary and plasma organic acids and amino acids in chronic fatigue syndrome. Clin Chem Acta. 2005;361:150–8.
59. Niblett SH, King KE, Dunstan RH, et al. Hematologic and urinary excretion anomalies in patients with chronic fatigue syndrome. Exp Biol Med (Maywood). 2007;232(8):1041–9.
60. Belensky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12–9.
61. Murray MF. Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus. Clin Infect Dis. 2003;36(4):453–60.
62. Regland G, Andersson M, Abrahamsson L, Bagby J, Dyrehag LE, Gottfries CG. Increased concentrations of homocystine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scand J Rheumatol. 1997;26(4):301–7.
63. Ortancil O, Sanli A, Eryuksel R, Basaran A, Ankarali H. Association between serum ferritin level and fibromyalgia syndrome. Eur J Clin Nutr. 2010;64(3):308–12.
64. Ali A, Njike VY, Northrup V, et al. Intravenous micronutrient therapy [Myers’ Cocktail] for fibromyalgia: a placebo-controlled pilot study. J Altern Complement Med. 2009;15(3):247–57.
65. Bell David S. Cellular Hypoxia and Neuro-immune Fatigue. Livermore: Wingspan Press; 2007.
66. Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Translational Medicine. 2011;9:81.
67. Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust. 1989;151(3):122–4.
68. von Bubnoff D, Hanau D, Wenzel J, et al. Indoleamine 2, 3-dioxygenase—expressing antigen presenting cells and peripheral T-cell tolerance: another piece to the atopic puzzle? J Allergy Clin Immunol. 2003;112(5):854–60.
69. Vial T, Descotes J. Clinical toxicity of the interferons. Drug SAF. 1994;10(2):115–50.
70. Kerr JR, Gough J, Richards SC, et al. Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Gen Virol. 2010;91(Pt 4):893–7.
71. Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behave Immun. 2012;26(1):24–31.
72. Meeus M, Mistiaen W, Lampbrecht L, Nijs J. Immunological similarities between cancer and chronic fatigue syndrome: the common link to fatigue? Anticancer Res. 2009;29(11):4717–26.
73. Däubener W, Mackenzie CR. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol. 1999;467:517–24.
74. Shapiro JS. Does varicella-zoster virus infection of the peripheral ganglia cause Chronic Fatigue Syndrome? Med Hypotheses. 2009;73(5):728–34.
75. Mersky H. The importance of hysteria. Br J Psychiatry. 1986;149:23–8.